Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $330K fell 43.7% year over year, behind the -42.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.8% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -43.7% toward the trailing-twelve-month pace of -42.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.09M USD
- Year-over-year change
- -44.3%
- 4-year CAGR
- -20.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.09M | -44.3% |
| FY2024 | 2024-12-31 | 3.75M | -13.9% |
| FY2023 | 2023-12-31 | 4.35M | +21.9% |
| FY2022 | 2022-12-31 | 3.57M | -31.1% |
| FY2021 | 2021-12-31 | 5.18M | — |
Stock-Based Compensation vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's LTM Mar 2026 stock-based compensation of $1.83M is the smallest of the 8 companies compared; the peer median is $5.11M.
- Its year-over-year change of -42.1% is the 4th highest of 8, against a peer median of -43.4%.
- Over three fiscal years its annual growth of -16.4% compares with a peer median of -5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $9.79M | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $5.11M | +30.3% | -5.3% | 68.1% | |
| LTM Mar 2026 | $4.63M | -43.5% | +57.4% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| Peer median (excluding CGTX) | $5.11M | -43.4% | -5.3% | 50.5% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M |
| Change in Working Capital | 2.84M | (943K) | 4.85M | 1.29M | (3.46M) |
| Accounts Receivables | (1.11M) | (1.41M) | 2.39M | (1.41M) | (7.24M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.17M | (1.09M) | 0 | 0 | 3.51M |
| Other Working Capital | 1.79M | 1.56M | 2.46M | 2.69M | 270K |
| Other Non-Cash Items | (33K) | 0 | 318K | 195K | 41K |
| Operating Cash Flow | (3.63M) | (18.53M) | (16.02M) | (28.47M) | (24.59M) |
| Capital Expenditures | (27K) | (171K) | (147K) | (4K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 9K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (27K) | (171K) | (147K) | (4K) | 9K |
| Debt Repayment | (268K) | (1.4M) | (811K) | (739K) | (353K) |
| Common Stock Issued | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.25M | 1.62M | 0 | (46K) | (164K) |
| Financing Cash Flow | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M |
| Effect of Forex Changes | (11K) | (1K) | 4K | 0 | 0 |
| Net Change in Cash | 49.53M | (13.16M) | (11.64M) | (4.91M) | 11.99M |
| Free Cash Flow | (3.66M) | (18.7M) | (16.17M) | (28.48M) | (24.59M) |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.